---
schema_version: "secwatch.filing_event.v1"
accession: "0001326190-23-000017"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2023-03-21T23:59:59+00:00"
generated_at: "2026-06-17T22:02:29.495397+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Altimmune reports positive Week 24 interim data from Phase 2 obesity trial; pemvidutide up to 10.7% mean weight loss

## Summary
- Mean weight loss of 10.7% (placebo-adjusted 9.7%) at 2.4 mg dose at Week 24; p < 0.001 vs placebo.
- In subjects ≤115 kg baseline (75% of cohort), mean weight loss reached 11.9% at 2.4 mg dose.
- ~50% achieved ≥10% weight loss and ~20% achieved ≥15% at 1.8 mg and 2.4 mg doses.
- Phase 1b diabetes trial: 7.7% mean weight loss at 2.4 mg dose; no SAEs or discontinuations.
- GI AEs mostly mild/moderate; lower doses used without titration; one SAE at 2.4 mg (nausea/vomiting).

## SEC filing metadata
- accession: 0001326190-23-000017
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2023-03-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000017/0001326190-23-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000017/alt-20230321x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326190-23-000017
- JSON: https://secwatch.observer/filing/0001326190-23-000017.json
- Plain text: https://secwatch.observer/filing/0001326190-23-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.